Oppenheimer Asset Management Inc. Bluebird Bio, Inc. Transaction History

Oppenheimer Asset Management Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $98,793 - $201,814	-5,955 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$27.5 - $37.92 $15,015 - $20,704	-546 Reduced 8.4%	5,955 $258,000
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $1,343 - $1,706	39 Added 0.6%	6,501 $351,000
Q2 2020 Aug 11, 2020	BUY	$27.12 - $45.97 $5,179 - $8,780	191 Added 3.05%	6,462 $394,000
Q1 2020 May 08, 2020	BUY	$26.16 - $63.5 $46,355 - $112,522	1,772 Added 39.39%	6,271 $288,000
Q4 2019 Feb 07, 2020	SELL	$46.96 - $61.67 $28,269 - $37,125	-602 Reduced 11.8%	4,499 $395,000
Q3 2019 Oct 31, 2019	BUY	$59.47 - $93.1 $36,098 - $56,511	607 Added 13.51%	5,101 $468,000
Q2 2019 Aug 09, 2019	BUY	$75.84 - $105.21 $72,578 - $100,685	957 Added 27.06%	4,494 $572,000
Q1 2019 Apr 24, 2019	SELL	$64.44 - $104.11 $40,403 - $65,276	-627 Reduced 15.06%	3,537 $557,000
Q4 2018 Jan 30, 2019	BUY	$59.1 - $93.26 $246,092 - $388,334	4,164 New	4,164 $413,000
Q4 2017 Feb 07, 2018	SELL	$81.25 - $130.7 $731 - $1,176	-9 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $519 - $822	9	9 $1,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.